Growth hormone secretion timing in depression: clinical outcome comparisons.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Growth hormone (GH) secretion in the 100 minutes preceding sleep onset (preSO), as well as in the first half of the night (1st HN), was examined for a group of 13 healthy women and 43 women with recurrent depression who participated in a 3-year maintenance therapy study.

Depressed patients were divided into subgroups according to their maintenance treatment assignment (active drug or drug free) and treatment outcome (completing in remission or having a recurrence).

Who Took Part

According to the abstract, 13 women were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized study.

The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

What Was Measured

Depressed patients were divided into subgroups according to their maintenance treatment assignment (active drug or drug free) and treatment outcome (completing in remission or having a recurrence).

Topics PubMed links to this paper include Antidepressive Agents, Tricyclic, Depressive Disorder, Electroencephalography, Growth Hormone, Imipramine, Menstruation and Neurosecretory Systems.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 13 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Biological psychiatry), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.